0
Preliminary Program
Preliminary Program: SUNDAY MAY 21
Psychiatric News
Volume 41 Number 4 page 6-13
+

Registration/Course Enrollment Open

+

Industry-Supported Symposia

IS9. Differentiating Atypical Antipsychotics in the Treatment of Schizophrenia: From Theory to PracticeSupported by Pfizer Inc.

IS10. Fibromyalgia: Scientific Advances to Reduce the Burden of IllnessSupported by Eli Lilly and Co.

IS11. Expanding the Neurobiological and Neuropsychological Foundation of ADHD: Impact on Clinical PracticeSupported by Shire US Inc.

IS12. The Impact of Anxiety Disorders: A Case-Based Approach to Improving Outcomes and Removing StigmaSupported by Cephalon Inc.

IS13. New Vistas in Treatment-Resistant DepressionSupported by Pfizer Inc.

+

CME Courses 15-22

+

CME Courses 23-30

+

Exhibits Open

APA Member Center Open

Publishers' Bookfair Open

+

Business Meeting and Forum (voting members only)

+

CME Courses 31-37

+

Industry-Supported Symposia

IS14. New Developments in Schizophrenia: From Neurobiology to PublicHealthSupported by Solvay Wyeth Pharmaceuticals

IS15. Vital Signs in Psychiatry: A Perspective on Sleep Across the Life CycleSupported by Sepracor Inc.

IS16. Interrupting the Cycle of Vascular Disease and DepressionSupported by Forest Pharmaceuticals Inc.

IS17. Update on Insights From and Future Course of the Collaborative Depression StudySupported by Wyeth Pharmaceuticals

IS18. Misdiagnosis of Bipolar II: Methods for Screening Patients at Risk for Bipolar DisorderSupported by GlaxoSmithKline

IS19. Advances in the Understanding of the Dementia SpectrumSupported by Eisai Inc. and Pfizer Inc.

+

Lecture

L1. The Challenge of Employment-Related Psychiatric EvaluationsLiza H. Gold, M.D., AAPL/APA's Manfred S. Guttmacher Award Lecture

+

Opening Session and Presidential Address

+

Industry-Supported Symposia

IS20. Alzheimer's Disease: Challenging the Practice ParadigmSupported by Forest Pharmacueticals Inc.

IS21. Effectiveness of Antipsychotic Drugs in Chronic Schizophrenia: Complete Results of the CATIE TrialSupported by Eli Lilly and Co.

IS22. Pseudobulbar Affect: A Common Syndrome That Is Underrecognized, Misdiagnosed, and UndertreatedSupported by Avanir Pharmaceuticals

IS23. Advances in the Neurobiology and Therapeutics of ADHDSupported by Cephalon Inc.

IS24. Atypical Depression: Merging Evidence and Public PolicySupported by Bristol-Myers Squibb Co.

IS25. Insomnia From the Inside Out: From Neuroscience to Clinical Experience to Public PolicySupported by Pfizer Inc. and Neurocrine Biosciences Inc.

Interactive Graphics

Video

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Articles
Articles